New combo therapy shows promise in shrinking esophageal tumors before surgery
NCT ID NCT05176002
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether combining the immunotherapy drug camrelizumab with standard radiation before surgery can help shrink tumors in people with esophageal cancer. About 25 patients will receive the combination, then undergo surgery 4-8 weeks later. Researchers will check how many patients have a major or complete response, and monitor for side effects. Because this is a small, early trial, the results are preliminary and not yet proven.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Camrelizumab (a drug that helps the immune system fight cancer) combined with standard radiotherapy
- What this could lead to
- If this works, it could point toward a more effective pre-surgery treatment for esophageal cancer, potentially shrinking tumors and improving surgical outcomes.
- What could go wrong
- This is a very small, early-phase trial with only 25 participants, so results may not apply broadly. The treatment may cause side effects, and it's not yet clear if it's better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video call replace a clinic visit for cancer patients on radiotherapy?
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures